Home / Investors / Overview

Company Information

CymaBay Therapeutics (Nasdaq: CBAY)

We are a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need. We are evaluating seladelpar in primary biliary cholangitis (PBC). We also have a product program in earlier development that features a unique mechanism of action with potential in chronic diseases.

Stock Information

Last Change Volume

Shares Outstanding: 10,064,495
(as of March 3, 2014)

Company Information

CymaBay Therapeutics
7575 Gateway Blvd
Suite 110
Newark, CA 94560

Investor Relations

LifeSci Advisors, LLC
Hans Vitzthum
(617) 430-7578

Recent News


CymaBay Therapeutics Announces Three Presentations at The Liver MeetingĀ® 2022


CymaBay Therapeutics Hosting Virtual Analyst Day on September 22


CymaBay Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Upcoming Event

Nov 4 2022

The Liver MeetingĀ® 2022

November 4 - November 8, 2022

Washington, DC

Q2 2022 Quarterly Results